Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16878159 | 0.77 | — | — | |
| SCHEMBL16878626 | 0.75 | — | — | |
| SCHEMBL3936585 | 0.75 | — | — | |
| SCHEMBL3937266 | 0.70 | — | — | |
| SCHEMBL219949 | 0.70 | PKM (0.33) | — | |
| SCHEMBL14644342 | 0.69 | MET (0.33) | — | |
| SCHEMBL14644327 | 0.69 | CCNB2 (0.33) | — | |
| SCHEMBL1285336 | 0.69 | ALDH1A1 (0.39) | — | |
| SCHEMBL3932484 | 0.67 | — | — | |
| SCHEMBL12341491 | 0.67 | CCR1 (0.46) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2024-07-25 | — | — | US | claimed |
| CN-117777145-A | Pyrazinopyridazine fused ring compounds and preparation method thereof | 北京理工大学 | 2024-03-29 | — | — | CN | claimed |
| EP-3134458-B1 | PHOTOVOLTAIC CELL WITH BENZODITHIOPHENE-CONTAINING POLYMER | RAYNERGY TEK INC (TW) | 2023-11-01 | — | — | EP | claimed |
| EP-4242202-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-09-13 | — | — | EP | claimed |
| CN-116217558-A | GLP-1 receptor agonist, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | claimed |
| EP-3752492-B1 | FUNGICIDAL OXADIAZOLES | BAYER AG (DE) | 2022-12-21 | — | — | EP | claimed |
| CN-114763352-A | GLP-1 receptor agonist and application thereof in medicine | 海思科医药集团股份有限公司 | 2022-07-19 | — | — | CN | claimed |
| WO-2022111624-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-06-02 | — | — | WO | claimed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | claimed |
| EP-2303824-A1 | 2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | Edison Pharmaceuticals, Inc. (US) | 2011-04-06 | — | — | EP | claimed |
| US-20100061928-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2010-03-11 | — | — | US | claimed |
| WO-2009158348-A1 | 2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | claimed |
| EP-2046789-A2 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-04-15 | — | — | EP | claimed |
| WO-2008012782-A2 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2008-01-31 | — | — | WO | claimed |
| WO-2006061428-A2 | GABA-A ALPHA 2 AND ALPHA 3 RECEPTOR AGONISTS FOR TREATING NEUROPATHIC, INFLAMMATORY AND MIGRAINE ASSOCIATED PAIN | Universität Zürich (CH) | 2006-06-15 | — | — | WO | claimed |
| EP-0145337-B1 | ELECTROCHROMIC DEVICES | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1990-08-08 | — | — | EP | claimed |
| EP-0096723-B1 | BATTERIES FABRICATED WITH ELECTROACTIVE POLYMERS | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1988-08-10 | — | — | EP | claimed |
| US-4613211-A | REVERSE COLOR CHANGING POLYMER FILM AS DISPLAY ELECTRODE | CHEVRON RESEARCH COMPANY (US) | 1986-09-23 | — | — | US | claimed |
| US-4579679-A | Electroactive polymers | CHEVRON RESEARCH COMPANY (US) | 1986-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GLP1R, GIPR, GCGR | MAPK1 241/4885 |
| US-20100061928-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | HRH3, H1-3, HRH4 | MAPK1 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.